Re-graft patency and clinical efficacy of aprotinin in elective bypass surgery

Vascular

Volumn 5, Issue 6, 1997, Pages 604-607

  Lass, M ^a   Simic, O ^a   Ostermeyer, J ^a  

^a DEPARTMENT OF CARDIOLOGY   (Germany)

Author keywords

aprotinin; coronary artery bypass; graft patency

Indexed keywords

APROTININ; HEPARIN; PLACEBO; SODIUM CHLORIDE;

ANGIOGRAPHY; ARTICLE; BYPASS SURGERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ELECTIVE SURGERY; GRAFT OCCLUSION; GRAFT PATENCY; HUMAN; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGED; APROTININ; BLOOD LOSS, SURGICAL; CORONARY ANGIOGRAPHY; CORONARY ARTERY BYPASS; DOUBLE-BLIND METHOD; HUMANS; MALE; SERINE PROTEINASE INHIBITORS; SURGICAL PROCEDURES, ELECTIVE; VASCULAR PATENCY;

EID: 0031543333     PISSN: 17085381     EISSN: None     Source Type: Journal    
DOI: 10.1177/096721099700500610     Document Type: Article

References (14)

1. Bistrup B. P., Royston D., Sapsford R. N., Taylor K. M., Cosgrove D. M., Reduction in blood loss and blood use after cardiopulmonary bypass with high-dose aprotinin. Journal of Thoracic and Cardiovascular Surgery, 1989, 97, 369–372.
2. Bidstrup B. P., Harrison J., Royston D., Taylor K. M., Treasure T., Aprotinin therapy in cardiac operations: A report on use in 41 cardiac centres in the United Kingdom. Annals of Thoracic Surgery, 1993, 55, 971–976.
3. Blauhut B., Boss C., Necek S., Doran J. E., Spath P., Hansen P. L., Effects of high-dose aprotinin on blood loss, platelet function, fibrinolysis, complement and renal function after cardiopulmonary bypass. Journal of Thoracic Cardiovascular Surgery, 1991, 101, 958–967.
4. Dietrich W., Barakay A., Dilthey G., Henze R., Niekau E., Sebening F., Richter J. A., Reduction of homologous blood requirement in cardiac surgery by intraoperative aprotinin application. Thoracic and Cardiovascular Surgeon, 1989, 37, 92–98.
5. Lemmer J. H., Stanford W., Bonney S. L., et al, Aprotinin for coronary bypass operations: Efficacy, safety and influence on early saphenous vein graft patency. Journal of Thoracic Cardiovascular Surgery, 1994, 107, 543–553.
6. Royston D., The serine antiprotease aprotinin (Trasylol): A novel approach to reducing postoperative bleeding. Blood Coagulation and Fibrinolysis, 1990, 1, 55–59.
7. Royston D., High-dose aprotinin therapy: A review of the first five year's experience. Journal of Cardiothoracic Anesthesiology, 1992, 16, 76–100.
8. Van Oeveren W., Hansen J. G., Bidstrup B. P., Effects of aprotinin on hemostatic mechanism during cardiopulmonary bypass. Annals of Thoracic Surgery, 1987, 44, 640–645.
9. Cosgrove D. M., Heric B., Lytle B. W., Taylor P. C., Novoa R., Golding L. A. R., Steward R. W., McCarthy P. M., Loop F. D., Aprotinin therapy for reoperative myocardial revascularization: A placebo-controlled study. Annals of Thoracic Surgery, 1992, 54, 1031–1038.
10. Bohrer H., Fleisher F., Lang J., Early formation of thrombi on pulmonary artery catheters in cardiac surgical patients receiving high dose aprotinin. Journal of Cardiothoracic Anesthesiology, 1990, 4, 222–225.
11. Bidstrup B. P., Underwood R. S., Sapsford R. N., Effect of aprotinin on aortocoronary bypass graft patency. Journal of Thoracic Cardiovascular Surgery, 1993, 105(1), 147–153.
12. Jegaden O., Vedrinne C., Rossi R., Aprotinin does not compromise arterial graft patency in coronary bypass operation. Journal of Thoracic Cardiovascular Surgery, 1993, 106, 180–181.
13. Ollivier J. P. and the EPPAC group, Patency of aortocoronary bypass grafts at 6 months: A French multicentre study. Archives des Maladies du Coeur et des Vaisseaux, 1991, 84, 537–542.
14. Havel M., Grabenwöger F., Schneider J., Laufer G., Wollenek B., Owen A., Simon P., Teufelsbauer H., Wolner E., Aprotinin does not decrease early graft patency after coronary artery bypass grafting despite reducing postoperative bleeding and use of donated blood. Journal of Thoracic Cardiovascular Surgergy, 1994, 107, 807–810.